Abstract
11072 Background: Introduction of independent prognostic markers may play a significant role in future treatment of colorectal cancer (CRC). Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a glycoprotein, which acts as an inhibitor of all active matrix metalloproteinases. TIMP-1 can be measured in plasma, and it has previously been shown to carry independent prognostic value in patients with primary CRC. The purpose of the present study was to validate TIMP-1 as a prognostic marker in patients undergoing operation for primary CRC. Methods: In the present prospective study plasma samples were collected before surgery from 323 patients with primary CRC between 2000 and 2003. After collection of all samples TIMP-1 was determined using a thoroughly validated, in-house ELISA method. Recurrence and survival were registered and the association to plasma TIMP-1 levels was studied in a Cox multivariate model including age, disease stage, differentiation, lymphatic and vascular vessel invasion calculating hazar...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
